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ABSTRACT 
Objective: In the current research work, dipyridamole, a BCS class–II drug, was aimed to be formulated as floating controlled release microballoons 
using ethyl cellulose as polymer and span 80 as surfactant to improve the gastric retention of drug as the multi-particulate dosage forms have 
tremendous advantages over single unit dosage forms.  
Methods: Microballoons were prepared by the emulsion solvent evaporation method. Prepared microballoons were characterized for entrapment 
efficiency, particle size, floating behavior and drug release studies. The study of effect of various formulation and process parameters like surfactant 
concentration, solvent volume, the volume of internal phase, polymer concentration, rotation speed on the drug entrapment efficiency and particle 
size of the microballoons were carried by using Box–Benhken to optimize the formulated microballoons.  
Results: The smallest particle size of the microballoons was found to be 205.9 µm in the F32 formulation. The highest drug entrapment efficiency 
was found to be 93.4% in the F34 formulation. Buoyancy studies showed all the formulations have good floating characteristics that lasted for a 
minimum of 24 h. The maximum yield of microballoons was found in the F7 formulation with 91.8% yield. The final results were statistically treated 
using ANOVA and were found to be significant (p value<0.05).  
Conclusion: Thus, the obtained results and their statistical interpretations indicated floating microballoons of dipyridamole were formulated 
effectively. 
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INTRODUCTION  
Oral controlled release dosage forms have the potential to upkeep an 
effective concentration in the system for a longer duration. It provides 
ease in dosage administration to the patient but the benefits are yet 
obstructed due to the short gastric retention time (GRT) and the 
unpredictable rapid gastric rate may cause partial drug release in the 
absorption zone of the patient’s body hence, hampering the efficiency 
of the dosage. It has caused awaited development in oral 
gastroretentive drug delivery systems (GRDDS) [1]. 
Multi-particulate dosage form is one such approach so as to improve 
the bioavailability of the drug. A method to improve the gastric 
residence time is to incorporate the drug into a floating device that 
is less dense than the gastric fluid [2]. Uniform distribution of the 
multi particulate dosage in the gastric content could result in more 
reproducible absorption and a reduced risk of local irritation than 
single-unit dosage forms. Such prolonged gastric retention not only 
controls the time but also the space in the stomach by maintaining 
the delivery system positioned at a steady site and thereby properly 
delivering the drug. 
Dipyridamole is a phosphodiesterase inhibitor that blocks uptake 
and metabolism of adenosine by erythrocytes and vascular 
endothelial cells. Dipyridamole also potentiates the anti-aggregating 
action of prostacyclin. Dipyridamole, a non-nitrate coronary 
vasodilator that also inhibits platelet aggregation, is combined with 
other anticoagulant drugs, such as warfarin, to prevent thrombosis 
in patients with valvular or vascular disorders. Dipyridamole is also 
used in myocardial perfusion imaging, as an antiplatelet agent, and 
in combination with aspirin for stroke prophylaxis.  
Dipyridamole likely inhibits both adenosine deaminase and 
phosphodiesterase, preventing the degradation of cAMP, an 
inhibitor of platelet function. It belongs to BCS class–II drugs with 
low solubility and high permeability. Hence a controlled release 
formulation of dipyridamole helps in improving its bioavailability 
[3-7]. Hence formulating the dipyridamole into microballoons helps 
in increasing the gastric retention time, thereby maintaining 
constant plasma concentration. In the current research work, 
dipyridamole was formulated as floating microballoons to improve 
its gastric residence time, thereby enhancing its bioavailability. 
MATERIALS AND METHODS 
Materials  
Dipyridamole pure drug was received as a gift sample from Mankind 
Pharma, Hyderabad. Ethylcellulose, span 80, methanol, diethyl ether 
and liquid paraffin were purchased from SD Fine Chemicals Ltd, 
Mumbai. 
Methods 
Preparation of floating microballoons 
Experimental design 
In the current research work, micro balloons were prepared by the 
emulsion solvent evaporation method. The optimization of the 
influence of various formulation and process variables (independent 
variables) on the responses of microballoons was carried out by 
using the response surface model. The independent variables 
considered in this study were the polymer concentration, 
concentration of methanol in the internal phase, volume of the 
internal phase, concentration of surfactant in the external phase and 
speed of rotation. The responses opted were entrapment efficiency 
and particle size of microballoons. All the five variables were taken 
at three levels each and so the Box-Behnken design was selected and 
performed by employing Stat-Ease Design Expert software. 
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Method of preparation of floating microballoons 
The drug was added to the polymer which was dissolved in the 
mixture of methanol and diethyl ether and thereafter placed on the 
vertex mixture for 2 min to get the organic phase. Liquid paraffin 
was taken in another beaker and 0.0% or 0.25% or 0.5% v/v of span 
80 was added to it to get the oily phase. The oil phase was placed 
under constant stirring on a mechanical stirrer at an rpm of 
400/550/700 to which the organic phase was added drop by drop. 
The stirring was continued for 4-5 h until the organic solvents were 
evaporated completely to yield hollow microspheres. The obtained 
hollow microspheres were washed with petroleum ether to remove 
paraffin and then dried. The compositions of various formulations 
were shown in table 1 where Factor A represents the polymer 
concentration in the total weight of microspheres; Factor B 
represents the concentration of methanol in the internal phase, 
Factor C indicates the total volume of the internal phase, Factor D 
indicates the concentration of Span 80 (surfactant) and Factor E 
represents the speed in rpm [8-10]. 
Characterization of microballoons 
Determination of percentage yield of microballoons 
Prepared microballoons were collected and weighed. The weight of 
microballoons was divided by the total weight of all the nonvolatile 
components that were used in the preparation of the microballoons 
and multiplied by 100, which gives the % yield of microballoons. 
Percentage yield of floating micro balloons is represented by 
following formula. 
% yield =  
Actual weight of product
Total weight of drug and excipients
× 100
 
Table 1: Formulation codes with combinations of various factors according to Box–Behnken design 










1 24 F1 50.00 20.00 7.50 0.25 550.00 
2 25 F2 75.00 20.00 7.50 0.25 550.00 
3 21 F3 50.00 60.00 7.50 0.25 550.00 
4 40 F4 75.00 60.00 7.50 0.25 550.00 
5 31 F5 62.50 40.00 5.00 0.00 550.00 
6 36 F6 62.50 40.00 10.00 0.00 550.00 
7 7 F7 62.50 40.00 5.00 0.50 550.00 
8 16 F8 62.50 40.00 10.00 0.50 550.00 
9 15 F9 62.50 20.00 7.50 0.25 400.00 
10 20 F10 62.50 60.00 7.50 0.25 400.00 
11 5 F11 62.50 20.00 7.50 0.25 700.00 
12 3 F12 62.50 60.00 7.50 0.25 700.00 
13 18 F13 50.00 40.00 5.00 0.25 550.00 
14 6 F14 75.00 40.00 5.00 0.25 550.00 
15 26 F15 50.00 40.00 10.00 0.25 550.00 
16 19 F16 75.00 40.00 10.00 0.25 550.00 
17 28 F17 62.50 40.00 7.50 0.00 /400.00 
18 23 F18 62.50 40.00 7.50 0.50 400.00 
19 34 F19 62.50 40.00 7.50 0.00 700.00 
20 2 F20 62.50 40.00 7.50 0.50 700.00 
21 17 F21 62.50 20.00 5.00 0.25 550.00 
22 14 F22 62.50 60.00 5.00 0.25 550.00 
23 38 F23 62.50 20.00 10.00 0.25 550.00 
24 11 F24 62.50 60.00 10.00 0.25 550.00 
25 33 F25 50.00 40.00 7.50 0.00 550.00 
26 41 F26 75.00 40.00 7.50 0.00 550.00 
27 32 F27 50.00 40.00 7.50 0.50 550.00 
28 10 F28 75.00 40.00 7.50 0.50 550.00 
29 13 F29 62.50 40.00 5.00 0.25 400.00 
30 1 F30 62.50 40.00 10.00 0.25 400.00 
31 4 F31 62.50 40.00 5.00 0.25 700.00 
32 22 F32 62.50 40.00 10.00 0.25 700.00 
33 9 F33 50.00 40.00 7.50 0.25 400.00 
34 37 F34 75.00 40.00 7.50 0.25 400.00 
35 30 F35 50.00 40.00 7.50 0.25 700.00 
36 12 F36 75.00 40.00 7.50 0.25 700.00 
37 8 F37 62.50 20.00 7.50 0.00 550.00 
38 35 F38 62.50 60.00 7.50 0.00 550.00 
39 27 F39 62.50 20.00 7.50 0.50 550.00 
40 39 F40 62.50 60.00 7.50 0.50 550.00 
41 29 F41 62.50 40.00 7.50 0.25 550.00 
 
Drug entrapment efficiency and loading efficiency 
To determine loading efficiency, microballoons were taken, 
thoroughly triturated and 100 mg drug equivalent microballoons 
were placed in 100 ml beaker containing 50 ml of 0.1N HCL. The 
beaker was subjected to constant stirring on a magnetic stirrer at 
100 rpm. After 3 h, the sample was withdrawn and the absorbance 
was measured at 283 nm against 0.1N HCL as blank by thermo UV 
spectrophotometer. Percentage of drug entrapment and the 
percentage loading efficiency were calculated as following:  
DEE =  
Amount of drug actually present
Amount of drug taken
× 100 
LoadingEf iciency(%) =
Amount of drug actually present
Theoretical amount of drug + polymer
× 100 
Floating characterization  
From each formulation, 100 microballoons were taken in a 100 ml 
beaker containing 70 ml of water and allowed to stand for about 24 
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h. After 24 h, the number of microballoons floating on the surface 
was observed [11-15]. 
% Buoyancy =
No. of  loated microballoons after 24h
No. of  loating microballoons taken
× 100 
Particle size and surface morphology 
The particle size analysis of all the formulations was carried by 
optical microscopy. The formulation with the highest drug 
entrapment efficiency was subjected to surface morphology analysis 
using scanning electron microscope [16].  
Drug release studies  
F7, F21and F34 microballoons with high entrapment efficiency were 
subjected to in vitro dissolution studies in USP II paddle-type dissolution 
test apparatus using 900 ml of 0.1N HCl as the dissolution medium and 
the rpm was maintained at 100. The samples were withdrawn at 30 min, 
1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 h and the samples were analyzed by using 
a UV-Visible spectrophotometer at the maximum wavelength of 283 nm 
after suitable dilutions [17]. 
Drug release kinetic studies 
The mechanism of drug release from the micro balloons was studied 
from the data obtained from in vitro release studies, which were 
fitted to various kinetic equations. The kinetic models used are:  
Qt = K0 t (zero-order equation) 
ln Qt = ln Q0-K1 t (first-order equation) 
Qt = Kh t1/2 (Higuchi equation) 
Where Qt is the amount of drug release in time t, Q0 is the initial 
amount of drug in the microsphere, and K0, K1, and Kh are rate 
constants of zero order, first order and Higuchi equations 
respectively. Further to confirm the mechanism of drug release, the 
first 60% of drug release was fitted in Korsmeyer-Peppas model. 
Mt/M∞= k tn 
where Mt is the amount of drug release at time t and M∞ is the 
amount release at time t=∞; thus Mt/M∞ is the fraction of drug 
released at time t, k is the kinetic constant, and n is the diffusion 
exponent which can be used to characterize both mechanisms of 
solvent penetration and drug release. 
Experimental design validation and ANOVA 
The optimization of the formulation and process parameters which 
influence different characteristics of microballoons can be achieved 
effectively only by the application of different statistical techniques. 
The various experimental designs that can be applied to the 
optimization of the parameters include empirical models, factorial 
designs [18], fractional factorial designs, simplex optimization, and 
response surface methodology [19]. All the combinations of factors 
were taken in a single block with one center point per block to attain 
a total of 41 runs as given by the Box-Behnken design of the 
response surface method [20]. Linear model of ANOVA was 
performed to identify whether the selected factors were significant 
or not individually and also together [21]. 
 
Table 2: Results of some physical characterization studies of floating microspheres 
S. No. Formulation Entrapment efficiency (%) Loading efficiency (%) Particle size (µm) Buoyancy (%) Yield (%) 
1 F1 83.7±3.4 41.85±1.7 266.2±7.6 90.33±2.3 88.3±1.2 
2 F2 92.4±1.6 23.1±0.4 210.3±4.9 88.67±1.7 86.3±2.3 
3 F3 78.3±2.8 39.15±1.4 281.5±5.3 91.33±3.3 84.2±1.8 
4 F4 88.7±1.9 22.18±0.5 453.2±10.2 86.00±2.7 84.5±1.5 
5 F5 81.5±5.1 30.56±1.9 468.1±6.4 89.00±2.1 89.7±1.4 
6 F6 77.1±4.2 28.91±1.6 362.5±7.1 94.67±1.7 81.4±3.1 
7 F7 92.8±2.5 34.8±0.9 353.6±8.2 93.67±3.0 91.8±3.5 
8 F8 75.2±1.9 28.2±0.7 216.8±6.0 91.67±2.4 82.3±2.8 
9 F9 91.5±2.4 34.31±0.9 471.1±9.2 93.33±3.7 79.9±1.7 
10 F10 89.3±3.1 33.48±1.2 422.8±8.7 94.00±1.8 84.6±1.9 
11 F11 82.7±2.2 31.01±0.8 244.3±8.1 96.00±2.6 81.1±2.4 
12 F12 78.6±4.1 29.47±1.5 315.6±3.4 91.33±3.3 91.5±1.1 
13 F13 83.3±1.7 41.35±0.8 345.4±7.2 89.67±2.8 88.2±2.8 
14 F14 92.4±3.2 23.1±0.8 455.8±8.0 86.33±1.9 76.4±3.2 
15 F15 77.5±5.4 38.75±2.7 231.5±6.4 88.33±1.5 82.4±4.2 
16 F16 80.2±6.3 20.05±1.6 329.6±8.9 94.33±1.3 86.3±1.6 
17 F17 85.1±2.1 31.91±0.8 452.1±9.2 87.67±1.7 79.6±2.2 
18 F18 92.3±1.7 34.61±0.6 391.5±5.9 89.67±2.7 78.8±2.7 
19 F19 78.9±3.5 29.58±1.3 322.4±4.9 92.00±2.3 84.1±1.6 
20 F20 85.7±3.8 32.13±1.4 211.6±3.7 85.00±3.1 91.2±2.8 
21 F21 94.1±3.9 35.28±1.5 409.2±5.6 91.00±3.0 77.9±2.4 
22 F22 91.1±4.5 34.16±1.7 402.0±6.9 95.33±2.6 84.7±2.5 
23 F23 84.5±4.1 31.68±1.5 299.5±3.8 94.00±2.4 86.5±1.6 
24 F24 83.1±6.2 31.16±2.3 307.2±4.7 90.67±4.1 84.4±1.9 
25 F25 76.8±4.3 38.4±2.1 331.3±5.1 88.33±2.7 79.1±2.2 
26 F26 85.8±5.7 21.45±1.4 486.5±8.4 87.67±4.3 78.1±2.7 
27 F27 78.4±5.2 39.2±2.6 219.9±8.9 93.33±3.9 86.7±2.3 
28 F28 91.5±4.4 22.88±1.1 432.1±3.7 93.00±4.3 85.5±3.1 
29 F29 92.4±3.2 34.65±1.2 593.2±6.2 89.33±3.7 82.4±3.0 
30 F30 78.1±3.1 29.28±1.2 342.2±6.3 88.67±2.3 82.6±1.6 
31 F31 77.6±2.4 29.1±0.9 345.6±4.4 96.67±1.7 86.8±1.9 
32 F32 73.8±2.6 27.67±1.0 205.9±5.0 95.67±1.9 91.2±2.1 
33 F33 86.1±1.9 43.05±1.0 362.4±7.8 91.33±2.5 87.3±3.2 
34 F34 93.4±1.8 23.35±0.4 628.6±8.4 92.33±2.7 81.1±3.1 
35 F35 74.2±2.4 37.1±1.2 215.7±5.7 87.00±3.1 78.5±2.9 
36 F36 84.7±3.1 21.18±0.8 358.2±8.2 93.33±2.0 79.8±1.9 
37 F37 86.4±2.9 32.4±1.1 395.3±9.6 93.67±2.2 83.9±2.4 
38 F38 84.8±2.7 31.8±1.0 449.8±4.6 91.00±3.7 89.7±1.6 
39 F39 90.6±4.1 33.97±1.5 294.7±5.8 85.00±4.1 79.2±1.3 
40 F40 88.1±4.3 33.03±1.6 332.2±7.3 89.67±4.4 87.4±2.1 
41 F41 81.2±1.8 30.45±0.7 342.6±7.9 91.33±3.1 89.1±2.5 
All the results are expressed as Average±standard deviation for n = 3. 
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RESULTS AND DISCUSSION 
Determination of percentage yield of microballoons 
The results of the percentage yield of dipyridamole microballoons 
were showed in table 2. All the formulations of microballoons were 
prepared by the solvent evaporation technique and from the results, 
more than 76.4% yield was observed in any case, which indicated 
that the solvent evaporation technique, along with the selected 
experimental conditions was highly effective for the preparation of 
floating microspheres. 
Drug entrapment efficiency and Percentage loading efficiency 
The drug entrapment efficiency of all the formulations was found to 
be above 73.8%, inferring a considerably better entrapment of the 
drug in the polymer matrix occurred as shown in table 2. The 
maximum drug entrapment efficiency was found to be in the 
formulations F7, F21 and F34, having drug entrapment efficiency 
above 92.8%. The percent loading efficiency of the drug in different 
formulated microballoons was shown in table 2 and the loading 
efficiency for all the microballoons were found to be within a range 
of 21% to 44%. 
 
 
Fig. 1: Contour plot of effect of polymer concentration and volume of internal phase on entrapment efficiency 
 
 
Fig. 2: Contour plot of effect of surfactant concentration and speed on entrapment efficiency 
 
The influence of different formulation and process parameters on 
the drug entrapment efficiency was plotted as contour plots using 
Design Expert software shown in fig. 1 and 2. It was depicted from 
fig. 1 that the drug entrapment efficiency was found to increase with 
the increase in the concentration of polymer which might be 
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polymer, which might hold the drug tightly and hinder the leakage of 
the drug, thus finally resulting in increased entrapment efficiency. 
The results obtained were correlated with those reported by 
Krishnamachari Y et al. [22]. Upon an increase in the concentration 
of methanol in the internal phase, the rate of evaporation might be 
decreased because of the higher melting point of methanol than that 
of diethyl ether. During slow evaporation for longer time, more 
amount of drug might be diffused out of the microspheres thus 
resulted in decreased entrapment efficiency.  
Fig. 2 infers that the drug entrapment efficiency of the microballoons 
increased as the concentration of the surfactant was increased, 
which might be due to the fact that as the surfactant concentration 
increases, the stability of the emulsion increases, which helps in the 
deposition of polymer efficiently on the globule thereby increasing 
the drug entrapment efficiency. This effect of surfactant on 
entrapment efficiency was correlated with that reported by 
Dinarvand R et al. [23] and Rojas J et al. [24]. As the speed of rotation 
of the mixing was increased, the entrapment efficiency decreased 
because at high rpm; there might be rapid solvent evaporation, 
which might lead to more amount of drug out of the globules along 
with the solvent. The drug entrapment efficiency results data of the 
dipyridamole microballoons obtained from the experimental data 
were statistically treated using analysis of variance and it was 
inferred from table 3 that the hypothetical statistical difference was 
significant for all the factors affecting the drug entrapment efficiency 
of the formulated dipyridamole microballoons as the p-value was 
found to be<0.05. 
  
 
Fig. 3:SEM images of floating microspheres of formulation F34 indicating a) Surface morphology and b) Surface dents that indicate inside 
of the microspheres is hollow 
 
Table 3: Anova for entrapment efficiency and Particle size of the dipyridamole microballoons 
Response Source SS Df MSS F–value p–value Inference 
Entrapment 
efficiency 
Model 1122.35 5 224.47 22.17 <0.0001 Significant 
A 313.29 1 313.29 30.95 <0.0001 Significant 
B 35.70 1 35.70 3.53 0.0688 Significant 
C 358.16 1 358.16 35.38 <0.0001 Significant 
D 91.20 1 91.20 9.01 0.0049 Significant 
E 324.00 1 324.00 32.00 <0.0001 Significant 
Residual 354.34 35 10.12    
Particle size Model 3.290 x105 5 65800.52 29.43 <0.0001 Significant 
A 75680.01 1 75680.01 33.84 <0.0001 Significant 
B 8728.23 1 8728.23 3.90 0.0561 Significant 
C 72589.83 1 72589.83 32.46 <0.0001 Significant 
D 41575.21 1 41575.21 18.59 0.0001 Significant 
E 1.304Ex105 1 1.304Ex105 58.33 <0.0001 Significant 
Residual 78266.57 35 5.651x10-4    
 
Floating characterization 
Upon observing the buoyancy of all the formulated microballoons 
for a period of 24 h, the percent buoyancy of all the microballoons 
was found to be 85% and above as shown in table 2 indicating that 
the selected formulation and experimental conditions were suitable 
to develop floating microballoons. This was further evidenced by the 
results of SEM studies (fig. 3) that the microparticles had surface 
dents which indicated hollowness inside the particles. 
Particle size and size distribution 
Fig. 3 depicts the SEM analysis conducted for the formulation 
F34. SEM analysis pictures of fig. 3 indicate the presence of a 
smooth surface of the microballoons with the presence of 
surface dents inferring the presence of hollowness inside the 
microballoons. 
It was inferred from fig. 4 that upon an increase in volume of 
internal phase, the particle size was found to be decreased which 
might be attributed to decrease in the viscosity of the internal phase 
at higher volume of solvent that might result in the fine globule 
formation in the emulsion, thus finally lead to the decrease in the 
size of the microspheres. With increase in polymer concentration, 
the particle size was found to be increased which might be due to 
the increased viscosity of the dispersion at high amount of polymer 
that might inversely affect the fine globule formation in the 
emulsion, hence lead to the increase in the size of the microspheres. 
This was evidenced by the results reported by Sharma N et al. [25]. 
It could be inferred from fig. 5 that upon increase in the concentration 
of surfactant, the particle size was found to be reduced, which may be 
attributed to the reduction of aggregation of globules in the emulsion. 
Upon increase in the speed of rotation, the particle size was found to 
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be reduced, which might be attributed to the more energy input into 
the emulsion at higher speed that must have lead to the formation of 
smaller globules in the emulsion, which finally might have lead to the 
formation of microspheres of smaller size upon evaporation of the 
solvent. The obtained results were correlated with the reports of 
Srikar G et al. [26]. From the results of ANOVA (shown in table 3), the 
effect of all the factors on particle size was found to be significant as 
the p-value is less than 0.05 for all the factors. 
 
 
Fig. 4: Contour plot showing the effect of polymer concentration and volume of internal phase on particle size 
 
 
Fig. 5: Contour plot showing the effect of concentration of surfactant and speed on particle size 
 
Drug release and release kinetic studies 
The results of drug release studies and release kinetic studies were 
shown in table 4. Among all the formulations, F34 showed maximum 
control of drug release with a release rate constant of 0.096 hr-1 and 
F15 showed the least control with a release rate constant of 0.251 h. 
Drug release from all the formulations followed first-order kinetics 
and release mechanism was found to be non-fickian diffusion. 
 
Table 4: Drug release kinetics of dipyridamole microballoons 
S. No. Formulation Regression values Peppas ‘n’ 
value 
Drug release rate 
constant (k h) Zero-order First-order Higuchi 
1 F7 0.863 0.985 0.971 0.704 0.142 
2 F21 0.904 0.992 0.941 0.81 0.145 
3 F34 0.935 0.905 0.981 0.894 0.096 
 
Experimental design validation and ANOVA 
Box–Behnken design was used for the development of the 
dipyridamole microballoons as it is advantageous over the full 
factorial designs because in the full factorial design, the number of 
runs will increase when the number of factors and levels taken were 
increased where as in the box–Behnken design, the same conclusion 
of results can be obtained for a less number of trials. It can be 
inferred from table 3 that the model was found to be significant 
through statistical analysis by ANOVA as the p–value was found to 
be<0.05.  
CONCLUSION 
In the current work, we developed microballons with high 
entrapment efficiency and relatively small-sized particles. Influence 
of various formulation and process parameters on entrapment 
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one of the most important characteristics of particulate drug 
delivery systems and it decides the weight of the formulation to be 
taken in order to have the required dose. The experiment was 
designed according to Box–Behnken design under response surface 
methodology and performed. The obtained results suitably analyzed 
by ANOVA and found that all the selected factors were found to have 
a significant influence on entrapment efficiency and hence the major 




The research idea was set with guidance of Dr. A. Ramu, Prof. Dr. S. 
Vidyadhara. The research work was done by Seelam Ramya Krishna. 
The manuscript was prepared by Seelam Ramya Krishna and the 
critical revision of the manuscript was done by Dr. A. Ramu, Prof. Dr. 
S. Vidyadhara. 
CONFLICT OF INTERESTS 
Declare none 
REFERENCES 
1. Foda NH, Ali SM. Gastroretentive drug delivery systems as a 
potential tool for enhancing the efficacy of antibiotics: a review. 
Int J Pharm Bio Sci 2011;2:94-104. 
2. Anepu S, Duppala L, Sundari MS. Formulation development, 
characterization, and in vitro evaluation of floating matrix 
dosage form of tramadol hydrochloride using various 
polymers. Asian J Pharm Clin Res 2017;10:281-90. 
3. Mohanraj Palanisamy, Jasmina Khanam, N Arun Kumar, C Rani. 
Chitosan microspheres encapsulated with metoprolol 
succinate: formulation and in vitro evaluation. Res J Pharm 
Tech 2009;2:349-52.  
4. Pandey A, Kumar G, Kothiyal P, Barshiliya Y. A review on 
current approaches in gastro retentive drug delivery system. 
Asian J Pharm Nursing Med Sci 2012;2:60-77. 
5. Chinna Gangadhar B, Shyam Sunder R, Vimal Kumar Varma M, 
Sleeva Raju M, Sai Kiran M. Formulation and evaluation of 
indomethacinmicrospheres using natural and synthetic 
polymers as controlled release dosage forms. Int J Drug 
Discovery 2010;2:8-16. 
6. Patil UK, Sahu R, Yadav SK. Formulation and evaluation of 
controlled release microspheres containing metformin 
hydrochloride. Res J Pharm Tech 2009;2:176-9. 
7. Kawatra M, Jain U, Ramana J. Recent advances in floating 
microspheres as a gastro-retentive drug delivery system: a 
review. Int J Adv Pharm Res 2012;2:5-23. 
8. Ritesh Kumar, Surbhi Kamboj, Amrish Chandra, Pawan Kumar 
Gautam, Vijay Kumar Sharma. Microballoons: an advance 
avenue for gastroretentive drug delivery system-a review. UK J 
Pharm Bio Sci 2016:4;29-40.  
9. Bhuvaneswari S, Manivannan S, Akshay M, Nify F. Formulation 
and evaluation of gastroretentive microballoons of 
acebrophylline for the treatment of bronchial asthma. Asian J 
Pharm Clin Res 2016;9:105-11. 
10. Kouchak Maryam, Ali Badrian. Preparation and in vitro 
evaluation of a microballoon delivery system for theophylline. 
Int J Pharm Res 2007;6:35-42. 
11. Durgapal S, Mukhopadhyay S, Goswami L. Preparation, 
characterization and evaluation of floating microparticles of 
ciprofloxacin. Int J Appl Pharm 2017;9:1-8. 
12. Chaturvedi AK, Verma A, Singh A, Kumar A. Formulation and 
characterization of microballoons of 
norfloxacin. J Drug Delivery Ther 2011;1:21-6. 
13. Bhardwaj P, Chaurasia H, Chaurasia D, Prajapati SK, Singh S. 
Formulation and in vitro evaluation of floating microballoons of 
indomethacin. Acta Pol Pharm 2010;67:291-8. 
14. Jain A, Pandey V, Ganeshpurkar A, Dubey N, Bansal D. 
Formulation and characterization of floating microballoons of 
nizatidine for effective treatment of gastric ulcers in the murine 
model. Drug Delivery 2015;22:306-11. 
15. Yadav A, Jain DK. Gastroretentive microballoons of metformin: 
formulation development and characterization. J Adv Pharm 
Technol Res 2011;2:51–5. 
16. Soni M, Majumdar A, Malviya N. Mucoadhesive chitosan 
microspheres of gefitinib. Int J Curr Pharm Res 2018;10:9-19. 
17. Srivastava AK, Ridhurkar DN, Wadhwa S. Floating 
microspheres of Cimetidine: Formulation, characterization and 
in vitro evaluation. Acta Pharm 2005;55:277–85. 
18. Gidwani B, Vyas A, Ahirwar K, Shukla S. Factorial design and a 
practical approach for gastro–retentive drug delivery system. 
Res J Pharm Tech 2016;9:641-9. 
19. Srikar G, Rani AP. Study on infuence of polymer and surfactant 
on in vitro performance of biodegradable aqueous-core 
nanocapsules of tenofovirdisoproxil fumarate by response 
surface methodology. Braz J Pharm Sci 2019;55:e18736. 
20. Shende MA, Marathe RP. Development and optimization of oral 
gastroadhesive matrices for diltiazem hydrochloride using 
some natural materials. Res J Pharm Tech 2016;9:817–30. 
21. Grandhi S, Rani AP, Pathuri R. Voriconazole solid lipid 
nanoparticles: Optimization of formulation and process 
parameters. Res J Pharm Tech 2018;11:2829-35. 
22. Krishnamachari Y, Madan P, Lin S. Development of pH-and 
time-dependent oral microparticles to optimize budesonide 
delivery to ileum and colon. Int J Pharm 2007;338:238-47. 
23. Dinarvand R, Moghadam SH, Sheikhi A, Atyabi F. Effect of 
surfactant HLB and different formulation variables on the 
properties of poly-D, L-lactide microspheres of naltrexone 
prepared by double emulsion technique. J Microencapsul 
2005;22:139-51.  
24. Rojas J, Pinto Aiphandary H, Leo E, Pecquet S, Couvreur P, Gulik A, 
et al. A polysorbate-based non-ionic surfactant can modulate 
loading and release of β-lactoglobulin entrapped in multiphase 
poly (dl-lactide-co-glycolide) microspheres. Pharm Res 
1999;16:255-60. 
25. Sharma N, Madan P, Lin S. Effect of process and formulation 
variables on the preparation of parenteral paclitaxel-loaded 
biodegradable polymeric nanoparticles: a co-surfactant study. 
Asian J Pharm Sci 2016;11:404-16. 
26. Srikar G, Shanthi D, Ramesh J, Kalyani V, Nagamma I. Floating 
microspheres: a prevailing trend in the development of 
gastroretentive drug delivery system. Asian J Pharm 
2018;12:235-42. 
 
